Targeted therapy or immunotherapy in BRAF-mutated metastatic melanoma : a Spanish center's decade of experience
Sun, Chen (Department of Radiation Oncology, The Second Affiliated Hospital of Zhengzhou University)
España, Sofia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Richarz, Nina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Solé-Blanch, Carme (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Boada, Aram (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Martínez Cardús, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Chu, Alan (Department of Radiation Oncology, The Second Affiliated Hospital of Zhengzhou University)
Liu, Zongwen (Department of Radiation Oncology, The Second Affiliated Hospital of Zhengzhou University)
Manzano, Jose Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Universitat Autònoma de Barcelona

Data:	2024
Resum:	Targeted therapies and immunotherapy are currently considered the mainstay first-line treatment for advanced BRAF-mutated melanoma. However, the impact of treatment (targeted therapy and immunotherapy) and the prognostic factors are still not clear. Medical records of 140 patients diagnosed with advanced melanoma between 2011 and 2021 were retrospectively reviewed to extract demographic, BRAF status, treatment, performance status, and survival data. ORR, PFS, and OS were compared between patients diagnosed with advanced melanoma and treated with first-line IT or BRAF/MEKi. The prognostic factors were assessed using Cox regression models. In all patients and those treated with immunotherapy, we did not find any effect of BRAF status on ORR, PFS, or OS. In patients with BRAF-mutated melanoma, ORR was 43. 8% vs. 70% (P=0. 04), PFS was 19. 2 vs. 11. 5 months (p=0. 22), and OS was 33. 4 vs. 16. 4 months for the immunotherapy and targeted therapy groups, respectively (P=0. 04). ECOG, presence of brain metastases, and high LDH level from initiation of first-line treatment were all associated with differences in PFS and OS. Patients with advanced BRAF-mutated melanoma treated with first-line immunotherapy had a significantly longer PFS and OS than those treated with first-line BRAF/MEKi; however, first-line BRAF/MEKi treatment had a significantly higher ORR than first-line immunotherapy.
Nota:	The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The first author received funding from Henan Provincial Health Commission, grant number LHGJ20220489, LHGJ20220828 for the article processing charges.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Target therapy ; Immunotherapy ; Melanoma ; BRAF mutation V600 ; Clinical experience
Publicat a:	Frontiers in Oncology, Vol. 14 (february 2024) , ISSN 2234-943X

DOI: 10.3389/fonc.2024.1322116
PMID: 38450188

11 p, 1007.0 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Articles de recerca
Articles > Articles publicats